moatshark My

All holdings

West Pharmaceutical Svsc

WST

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$160m
Combined value at quarter end
Last quarter
0 bought
0 sold or trimmed
Price at Q2 ’26 end
$359.00
+43.2% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+14.8%Q2 ’18
+24.3%Q3 ’18
-2.3%Q2 ’25
+19.9%Q3 ’25
+4.9%Q4 ’25
-8.9%Q1 ’26
+43.2%Q2 ’26
Q2 ’18: +14.8%; Q3 ’18: +24.3%; Q2 ’25: -2.3%; Q3 ’25: +19.9%; Q4 ’25: +4.9%; Q1 ’26: -8.9%; Q2 ’26: +43.2%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
1Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes West Pharmaceutical Svsc.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding West Pharmaceutical Svsc
Gates Foundation Trust0.5%$160m$160mUnchanged6 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of West Pharmaceutical Svsc
Bought or soldFiling
15 Sep 2026Favorite Annette FSr. VP & Chief HR Officer▼ Sold2,524$365.00$921kForm 4
14 Sep 2026Favorite Annette FSr. VP & Chief HR Officer▼ Sold2,500$355.00$888kForm 4
11 Sep 2026Favorite Annette FSr. VP & Chief HR Officer▼ Sold2,500$345.00$863kForm 4
8 Sep 2026Favorite Annette FSr. VP & Chief HR Officer▼ Sold2,818$340.81$960kForm 4
8 Sep 2026Favorite Annette FSr. VP & Chief HR Officer▼ Sold2,817$340.81$960kForm 4
8 Sep 2026Favorite Annette FSr. VP & Chief HR Officer▼ Sold2,500$340.81$852kForm 4

About the company

Sector
Health care · Surgical & Medical Instruments & Apparatus
Incorporated in
Pennsylvania
Financial year ends
31 December
Shares outstanding
70m at 20 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$1.4bn2013
$1.4bn2015
$1.6bn2017
$1.8bn2019
$2.8bn2021
$2.9bn2023
$3.1bn2025
2013: $1.4bn; 2014: $1.4bn; 2015: $1.4bn; 2016: $1.5bn; 2017: $1.6bn; 2018: $1.7bn; 2019: $1.8bn; 2020: $2.1bn; 2021: $2.8bn; 2022: $2.9bn; 2023: $2.9bn; 2024: $2.9bn; 2025: $3.1bn
West Pharmaceutical Svsc revenue and net income by year
YearRevenueNet income
2025$3.1bn$494m
2024$2.9bn$493m
2023$2.9bn$593m
2022$2.9bn$586m
2021$2.8bn$662m
2020$2.1bn$346m
2019$1.8bn$242m
2018$1.7bn$207m
2017$1.6bn–
2016$1.5bn–
2015$1.4bn–
2014$1.4bn–
2013$1.4bn–

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.